Background: A recent cross-sectional study demonstrated that convective-controlled double high-flux hemodiafiltration (CC-HDF) could yield equivalent removal of small and middle molecule uremic toxins to on-line hemodiafiltration (OL-HDF). Methods: The present study was conducted to compare the 1-year efficacy between CC-HDF (n = 10) and OL-HDF (n = 16) in chronic hemodialysis patients undergoing thrice weekly high-flux hemodialysis for at least 6 months. Results: When compared with baseline (high-flux hemodialysis), 1-year treatment with both HDF modes had comparable efficacy in significantly lowering serum pre-dialysis β2-microglobulin (β2m) levels (p < 0.05) and significantly enhancing greater urea reduction ratio (p < 0.05). Both HDF modes could comparably maintain the hematology profile, calcium-phosphorus metabolism, and nutritional status according to the K-DOQI guidelines. Conclusion: CC-HDF can provide equivalent 1-year efficacy to OL-HDF and would be an effective alternative mode to OL-HDF.

Keywords:
Hemodiafiltration, convective-controlled double high-flux, On-line hemodiafiltration, β2-Microglobulin
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.